Abstract
Self-monitoring of blood glucose (SMBG) in type 2 diabetic patients was compared across 14 countries. There was an unexpectedly high SMBG-use in non-insulin-treated patients. Reimbursement polices differed by country, region, insurance status, and patient income. More rigorous and systematic data collection is needed to ensure evidence-based SMBG-use.
Original language | English |
---|---|
Pages (from-to) | e15-e18 |
Journal | Diabetes Research and Clinical Practice |
Volume | 82 |
Issue number | 3 |
DOIs | |
Publication status | Published - 2008 |